INSIGHTS ON PHARMACEUTICAL INSPECTION

  • Integrity Testing Of Inhaler Products
    1/5/2026

    Ensuring inhaler integrity is vital for patient safety and regulatory compliance. Discover how Vacuum decay testing provides a sensitive, non-destructive method to detect leaks and maintain sterility.

  • Protecting Your Drug Product
    5/13/2026

    With patient lives depending on every dose, even minor vulnerabilities in containment or delivery systems can have serious consequences for product integrity and patient outcomes.

  • Physical Contamination Detection
    3/23/2026

    Learn how physical contaminants enter production lines and how detection systems like metal detection and X-ray inspection help prevent defects and recalls to strengthen quality control.

  • Advance Traditional CCIT With Dynamic Vacuum Decay
    5/22/2026

    Dynamic vacuum decay advances traditional CCIT by improving leak detection. Learn how controlled, variable vacuum conditions deliver greater sensitivity and more reliable insight into package integrity.

  • Planning For Scale-Up
    5/21/2026

    From rapid early-stage production to scalable commercialization, discover the packaging and continuity challenges companies face as they prepare for launch.

PHARMACEUTICAL INSPECTION SOLUTIONS

  • With our Switch 350, you benefit from the advantages of two machine concepts: We have combined the modularity, handling options, and technologies of our well-proven standard platforms with the flexibility of our small batch inspection machine to run syringes and vials on one and the same machine – with nesting system for syringes and vials alike.

  • Ensure accurate aerosol can filling with this aerosol checkweigher, with a precision of ± 10 mg and a capability of up to 150 cans per minute.

  • Parenteral packages require sensitive and reliable container closure integrity (CCI) testing. Discover the VeriPac leak detection instrument, an effective IV bag testing solution that utilizes vacuum decay technology.

  • As the governing regulatory document of the European Medicines Agency (EMA), EU GMP Annex 1 discusses a full host of concepts related to manufacture of sterile medicinal products. In contrast to guidance documents issued by the FDA, EU GMP Annex 1 is interpreted as law, requiring strict adherence to the regulatory expectations contained, numerous of which allude to container closure integrity testing. In fact, current proposed and ongoing revisions increase the expectations of scrutiny on package integrity.

  • Once material is packaged, secondary packaging is a crucial part of the preparation process. Ropack doesn’t leave anything to chance, with secondary contract packaging services to ensure your products are ready for market when you need them to be.